Drugs / KRAS-EphA-2-CAR-DC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05631899 | Apr 2023 → Jun 2026 overdue | cancer | Chinese PLA General Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KRAS-EphA-2-CAR-DC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05631899 ↗ |
| Modality | Cell therapy | “Chimeric antigen receptor engineered dendritic cells” NCT05631899 ↗ |
| Route | Intravenous | “5\~10 × 10\^6 CAR-DCs per dose will be administered by intravenous injection.” NCT05631899 ↗ |